Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin

This phase 3, randomized, double-blind, double-dummy, active-controlled trial was conducted across 131 medical research centers and hospitals in Argentina, China, Japan, Mexico, and the United States. The study enrolled 1698 adults (≥18 years) with type 2 diabetes inadequately controlled with metformin (≥1500 mg per day), a baseline glycated hemoglobin (HbA1c) between 7.0% and 10.5% (53-91 mmol/mol), and a body mass index (BMI) of at least 25 kg/m². Participants were randomly assigned to one of four treatment arms for a 52-week treatment period.

The intervention was once-daily oral orforglipron at doses of 12 mg or 36 mg. The comparator was once-daily oral semaglutide at doses of 7 mg or 14 mg. All participants continued their background metformin therapy. The study employed a double-dummy design to maintain blinding.

The primary outcome was the mean change from baseline in HbA1c at week 52, assessed for non-inferiority with a margin of 0.3% in the intention-to-treat population. Using the treatment regimen estimand, the mean baseline HbA1c was 8.3%. At week 52, the mean change was -1.71% (SE 0.07) for orforglipron 12 mg, -1.91% (SE 0.08) for orforglipron 36 mg, -1.23% (SE 0.05) for semaglutide 7 mg, and -1.47% (SE 0.06) for semaglutide 14 mg. The estimated treatment differences demonstrated superiority of orforglipron: orforglipron 12 mg was superior to semaglutide 7 mg by -0.48% (95% CI -0.65 to -0.31, p<0.0001); orforglipron 36 mg was superior to semaglutide 14 mg by -0.44% (95% CI -0.62 to -0.26, p<0.0001). Cross-dose comparisons also favored orforglipron: orforglipron 12 mg vs. semaglutide 14 mg (-0.24%, 95% CI -0.41 to -0.072, p=0.0050) and orforglipron 36 mg vs. semaglutide 7 mg (-0.68%, 95% CI -0.85 to -0.50, p<0.0001).

Key secondary outcomes were not reported in the provided abstract data. Therefore, the comparative effects on other critical endpoints like body weight, fasting plasma glucose, or cardiovascular risk markers remain unknown from this summary.

Safety and tolerability findings showed a higher incidence of gastrointestinal adverse events with orforglipron. These events occurred in 249 of 424 participants (59%) on orforglipron 12 mg and 245 of 423 (58%) on orforglipron 36 mg, compared to 157 of 426 (37%) on semaglutide 7 mg and 193 of 425 (45%) on semaglutide 14 mg. Most events were mild to moderate. Discontinuation rates due to adverse events were higher with orforglipron: 37 of 424 (9%) for the 12 mg dose and 41 of 423 (10%) for the 36 mg dose, versus 19 of 426 (4%) for semaglutide 7 mg and 21 of 425 (5%) for semaglutide 14 mg. The abstract also noted a mean increase in pulse rate with orforglipron, though specific numerical data were not provided. Rates of serious adverse events were not reported.

These results position oral orforglipron as a potentially more potent glucose-lowering agent than the currently available oral GLP-1 receptor agonist, semaglutide. Prior landmark studies with injectable GLP-1 receptor agonists and oral semaglutide established this class as effective for glycemic control and weight loss. This trial suggests orforglipron could offer a new, highly effective oral option, though with a different tolerability profile.

Key methodological limitations include the presentation of data in abstract form, which lacks the full detail of a peer-reviewed publication. The absence of reported secondary outcomes, particularly body weight change, is a significant gap. The study duration of 52 weeks is adequate for glycemic outcomes but may be insufficient to fully characterize long-term safety, especially cardiovascular effects. The population was limited to those on metformin monotherapy, so results may not generalize to patients on other background regimens or with different comorbidities.

The clinical implications are that orforglipron, if approved, may represent a more potent oral alternative for HbA1c reduction in patients with type 2 diabetes inadequately controlled on metformin. However, clinicians must weigh its superior efficacy against a higher burden of gastrointestinal side effects and a higher rate of treatment discontinuation due to adverse events compared to oral semaglutide. The increase in pulse rate also warrants monitoring.

Several important questions remain unanswered. The full impact on body weight, a key driver for GLP-1 receptor agonist use, is unknown. Long-term cardiovascular and renal safety data are absent. The optimal dosing strategy and titration schedule to manage gastrointestinal tolerability are not defined. Furthermore, the cost-effectiveness and place in therapy relative to other advanced agents, including injectable GLP-1 receptor agonists and dual agonists, require future study.